Introduction. Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing nearly one-third of all pediatric cancers. 1 With the advent of aggressive multimodality therapy, it has become a curable disease in more than 80% of patients. (2) More than 75% of patients survive free of leukemia recurrence at least 5 years from diagnosis with current treatments that incorporate systemic chemotherapy and specific central nervous system preventive therapy, [3] [4] [5] [6] however, the treatment of ALL results in a significant morbidity and mortality. 2 The use of risk-adapted treatment protocols has improved cure rates while limiting the toxicity of therapy. 7 Angiogenesis is an important requirement for the development and progression of hematological malignancies including leukemia and lymphoma. 8 Vascular endothelial growth factor (VEGF) is an important cytokine that contributes to disease evolution in various neoplasms. In particular, VEGF has been described as a mediator of leukemia associated angiogenesis as well as an autocrine growth regulator in leukemic cells. 9 Neuropilin-1 (NRP-1/BDCA4/CD304) is a transmembrane C-type lectin found on plasmacytoid dendritic cells (pDCs). 10 It was initially identified as a receptor for class III semaphorins (SEMA3s) mediating neuronal guidance and axonal growth. 11 It was subsequently found to bind to VEGF that is a critical pro-angiogenic factor that induces proliferation and migration of endothelial cells to tumor vasculature. 12 Neuropilin-1 expression is reported to be specific for pDCs in humans 13 and has been found to be highly expressed in diverse solid tumors, as prostate, breast, pancreatic, lung, ovarian and gastrointestinal carcinomas. 14, 15 Increased expression of Neuropilin-1 has been correlated with tumor growth and invasiveness. 16 Furthermore, Neuropilin-1 expression is increased in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myeloid leukemia compared with normal bone marrow. 17 Neuropilin-1 also has been reported to be overexpressed in leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). 18 Therefore, NRP-1 could potentially be used as a target for ligand-directed therapy in leukemia and lymphoma.
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Aim of the Work. The objective of this work was to study the prognostic value of Neuropilin-1 expression in Egyptian children with B-lineage ALL.
Patients and Methods. The current study was carried out on fifty children after ethical committee approval and written consent of the parents in the Oncology Unit, Pediatric Department, Tanta University Hospitals from August 2010 to March 2014. This series included 32 males and 18 females with an age at diagnosis ranging from 3-17 years and mean value of 9 ± 3.5 years. This study was conducted on fifty patients with newly diagnosed B-lineage ALL attendants to Oncology Unit. Twenty healthy children, age and sex matched, serving as a control group, were also included in the study to estimate the expression of Neuropilin-1 on peripheral blood lymphocyte.
ALL patients were diagnosed on the basis of the clinical presentation, morphological and cytochemical evaluation of blood and marrow smears, together with immunophenotyping. Diagnosis was based on the presence of 20% or more blast cells in bone marrow (BM), according to WHO proposal and the immunophenotyping results consistent with ALL (19) with exclusion of Philadelphia chromosome-positive ALL cases from this study.
The laboratory examinations included: complete blood count, serum LDH levels, bone marrow aspiration, cytochemistry with Sudan black and Myeloperoxidase, immunophenotyping and estimation of Neuropilin-1 expression on blast cells by flow cytometry. The studied patients were treated according to standard protocols for B-lineage ALL 20 and were monitored during the period of follow-up that lasted for 42 months. 
Statistical analysis. Data were analyzed using SPSS version 20. Quantitative data were expressed in the form of mean and standard deviation while qualitative data were described in the form of number and percentage. Differences between groups were evaluated with student t-test for quantitative data and Chi-square test and ANOVA for qualitative data. The statistics and survival analysis were carried out according to Kaplan-Meier product limit estimates.
Results. There were 31 patients (62% of total) with positive NRP-1 expression (Neuropilin-present in ≥ 20% of blast population) and 19 patients (38% of total) with negative Neuropilin-1 expression (< 20% of BM blasts expressing Neuropilin-1) ( Table 1) .
There were no statistically significant differences between Neuropilin-1 positive and Neuropilin-1 Table 2) .
The studied patients were categorized on the basis of immunophenotyping into early pre-B ALL (32 cases, 64%) and pre-B ALL (18 cases, 36%). Neuropilin-1 was significantly higher in pre-B compared with early pre-B ALL patients ( Table 3) .
Thirty patients (60%) achieved and maintained complete remission (CR) till the end of the study; 12 patients (24%) suffered from relapse and eight patients died either during induction or maintenance therapy. A greater number of patients with complete remission were Neuropilin-1 negative than Neuropilin-1 positive (17/30). Most of ALL patients who relapsed, were Neuropilin-1 positive (10/12) with a mean expression percentage of 53.8±27.12 and all patients who died were positive for Neuropilin-1 at diagnosis (8 cases). Neuropilin-1 expression was significantly higher in relapsed patients and in patients who died during therapy when compared to patients who achieved complete remission ( Table 4) .
There was a statistically significant difference in prognosis between Neuropilin-1 positive and negative patients, with a significantly shorter overall survival (OS) and disease-free survival (DFS) in Neuropilin-1 positive B-lineage ALL patients ( Table 5 and Figure 2  and 3) . Discussion. Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing nearly one-third of all pediatric cancers. 1 With the advent of aggressive multimodality therapy, it has become a curable disease in over than 80% of patients, however, the treatment of ALL results in a significant morbidity and mortality. 2 The use of risk-adapted treatment protocols has improved cure rates while limiting the toxicity of therapy. 7 The present study measured Neuropilin-1 surface expression on BM blasts in 50 children with newly diagnosed B-cell ALL compared to normal peripheral blood lymphocytes from 20 healthy controls by flow cytometry.
Neuropilin-1 was expressed in all patients with Blineage ALL included in this study with variable degrees of expression ranging from 7.9% to 92.1% of BM blasts. 31 patients presented high Neuropilin-1 expression ≥ 20% ( range: 20.5-92.1) (Neuropilin-1 positive group) and 19 patients low expression, less than 20% of BM blasts ( range: 7.9-14.5) (Neuropilin-1 negative group), while expression in peripheral blood normal lymphocytes did not exceed 3.4%. A highly significant statistical difference in levels of Neuropilin-1 expression was found between ALL patients and controls and between positive and negative Neuropilin-1 expression groups of patients. This is in agreement with Karjalainen et al 2011 17 who examined Neuropilin-1 in patients with acute leukemia and demonstrated its expression, above baseline bone marrow levels, in all B-cell ALL samples and in two thirds of AML samples with stronger expression in blast cells of B-cell ALL than AML blast cells. 17 Similarly, Meyerson et al 2012 22 found that Neuropilin-1 is frequently expressed on B-ALL blasts (71%), whereas its expression is less frequent on AML blasts (22.9%) and consistently absent on peripheral blood lymphocytes. 22 The present study revealed that the mean percentage of expression of Neuropilin-1 in bone marrow blasts in B-lineage ALL patients was 36.86% overall. Neuropilin-1 expression was significantly higher in patients with pre-B acute lymphoblastic leukemia (74.04%) than patients with early pre-B ALL (23.55%).
This datum is in agreement with Meyerson et al 2012 22 who found that Neuropilin-1 is frequently expressed on B-ALL blasts, and weakly expressed in normal bone marrow B-cell progenitors, while gradually decreasing during maturation, to be completely lost at later stages of B-cell. The expression of Neuropilin-1 on B-cell progenitors may explain its frequent higher expression in precursor B-ALL than mature ALL. 22 In our study, Neuropilin-1 expression was significantly associated with higher white blood cells Count, BM blasts percentage, and serum LDH levels at diagnosis. There were significantly higher levels of Neuropilin-1 expression on bone marrow blasts at diagnosis in patients who subsequently relapsed or died during the period of follow-up compared to those who achieved and maintained complete remission. Also, patients with higher Neuropilin-1 expression had significantly shorter overall survival and disease-free survival than patients with low Neuropilin-1 expression. These results indicate that higher Neuropilin-1 expression levels correlated with disease severity and biologic progression in children with BLineage ALL. This datum is in agreement with previous studies establishing the poor prognostic impact of Neuropilin-1 expression also on AML. 9, 23, 24, 25 Importance of Neuropilin-1, as marker of disease in pediatric acute lymphoblastic leukemia, is further stressed by Beesley et al 2005 26 who identified Neuropilin-1 as a part of gene expression signature associated with relapse and adverse clinical outcome, and by Solly et al. 2012 27 who considered Neuropilin-1 an useful marker of minimal residual disease.
Conclusions.
Our findings suggest that Neuropilin-1 expression on bone marrow blasts is a valuable marker of bad prognosis in patients with B-lineage ALL. Therefore, we recommend the incorporation of Neuropilin-1 expression on bone marrow blasts in children with B-cell ALL as a prognostic marker, useful to categorize patients into the bad prognosis group and then candidate for an intensive treatment.
